Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28084205 | 0.88 | CYP2C9 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C9MAPT | |
| SCHEMBL12894347 | 0.88 | FFAR4 (0.48) | SMN1; SMN2NPC1RAB9AMAPTMRGPRX4 | |
| SCHEMBL8592978 | 0.85 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C9MAPT | |
| SCHEMBL12894376 | 0.85 | MAPT (0.46) | SMN1; SMN2NPC1RAB9ACYP2C9MAPT | |
| SCHEMBL12894353 | 0.84 | CDK4 (0.44) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL18241048 | 0.83 | CYP2C9 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C9MAPT | |
| SCHEMBL27814043 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C9MAPT | |
| SCHEMBL13794084 | 0.81 | KDM4E (0.51) | SMN1; SMN2NPC1RAB9ACYP2C9MAPT | |
| SCHEMBL12894381 | 0.81 | FFAR1 (0.39) | SMN1; SMN2NPC1RAB9AMAPTMRGPRX4 | |
| SCHEMBL27434536 | 0.81 | CYP2C9 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879889-B2 | administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-7879889-B2 | administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-7563903-B2 | Acylaminothiazole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | ACAT1, GLS2, GLS | SMN1; SMN2 658/4885NPC1 217/4885RAB9A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.